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ABSTRACT
The American University in Cairo
Gold Nanoparticles-Based Sensors for Detection of Mycobacterium tuberculosis
Genomic DNA
By: Amira Hazem Mohamed Mansour
Under the supervision of Prof. Dr. Hassan M.E. Azzazy

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), is an airborne disease
that strikes one third of the globe’s population. In addition to infection of 9.6 million
patients, TB claimed the lives of 1.5 million people in 2014 only. The majority of TB
patients are present in the third world where the balance between cost-effective

diagnostic method and prevalence of TB is difficult to achieve. Accurate diagnosis of
TB is necessary to timely initiation of treatment. The available diagnostic tools are
slow, while the rapid methods are either inaccurate or relatively unaffordable. So,
sometimes the diagnosis is presumptive based on the clinical findings and the
treatment is empiric. The treatment is lengthy and demands the administration of
multiple antibiotics. However, the emergence of drug resistance threatened the global
control programs of TB.
The objective of this work is to develop cheap, fast and accurate detection methods.
Two gold nanoparticles (AuNPs) based sensors were developed for colorimetric and
fluorometric detection of MTB. Seventy two anonymous sputum samples were
cultured then DNA was extracted. MTB H37Ra was the positive control while M.
smegmatis and 8 non-MTB and negative controls. Characterization of the samples
was achieved by multiplex PCR using MTB and NTM specific primers. Random
samples were amplified by 16S-23S ITS primers and sequenced. Drug resistance
associated mutations of MDR-TB were identified by MAS-PCR.
The colorimetric assay aim was the detection of amplified MTB DNA by cationic
AuNPs. The samples were amplified by IS6110 and rpoB primers. Only MTB
samples yielded amplicons. So the negatively charged dsDNA attracted the positively
charged AuNPs inducing their aggregation and the color turned blue. While the
iv

negative samples did not yield any amplicons and the AuNPs remained dispersed so
the color was red. The sensitivity and specificity was 100% and the detection limit
was 5.4 ng/μl of MTB DNA.
The fluorometric assay exploited the quenching property of 40 nm AuNPs. The
unamplified DNA was fragmented in the presence of 16s rDNA specific probe tagged
with the fluorophore CY-3 by sonication and denatured for 3 min at 95 ºC followed
by annealing at 52ºC for 45 sec. Then AuNPs were added and the fluorescence was
measured. By FRET, the relative fluorescence was calculated revealing a cut-off
value of 3. In MTB samples, the CY3-16s rDNA specific probe hybridized with its
target and became spaced from the AuNPs allowing high fluorescence to be detected.
Due to the lack of target-probe hybridization in the negative samples, the AuNPs were
adsorbed on the probe and thus the fluorescence is quenched. Thirteen samples were
chosen randomly, amplified and sequenced. Sequencing confirmed that 12/13 samples
were MTB with 100% concordance with the multiplex PCR and FRET. The assay had
sensitivity and specificity of 98.6% and 90% respectively and concordance of 98%
with multiplex PCR. The detection limited was calculated to be 10 ng/ul. In
conclusion, two AuNPs based sensors were developed to allow low cost and rapid
detection of MTB on low source settings. The assays are rapid, sensitive and can have
great

potential

in

clinical

practice

for

TB

diagnosis.
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Chapter 1: Introduction and literature review
1.1. History of Tuberculosis (TB)
Egyptian mummies 4000 years old revealed that TB was a common infection in
ancient Egypt. It was also described by ancestor Assyrians and the Greeks.
Mycobacterium tuberculosis (MTB) is believed to be a soil-living microorganism and
developed to infect humans after serial mutations. It is postulated that the spread of
TB to Europe was caused by the travelling of animals’ merchants. Later in the modern
history, TB killed quarter of Europe population in one of the most sever pandemics.
Better medical precautions and then the introduction of the Bacillus Calmette-Guerin
(BCG) vaccine sharply declined the morbidity and mortality rate [1]. Unfortunately,
TB infection spread again due the development of drug resistance strains and the
human immunodeficiency virus (HIV) pandemics especially in Africa where there are
now high number patients co-infected with HIV and TB [1, 2].

1.2. Tuberculosis (TB)
According to the 2014 World Health Organization (WHO) tuberculosis report, l.5
million patients lost their lives to TB, of which one quarter were co-infected with
HIV. This number exceeded the death rate of HIV alone which was 1.2 million people
for the same year (figure 1). It is postulated that 9.6 million people carry MTB bacilli
worldwide of which two thirds were infected in 2014 only (figure 2) [3]. According
to the WHO reports about the incidence of TB in Egypt, half of the patients are still
undiagnosed. In 2014, the incidence is 13 patients per 100,000 and the estimated
number is 11,700 people with 1% MDR-TB and 6% of the patients are children
(figure 3) [4]. TB is a contagious disease of the respiratory system and may progress
to be extra pulmonary infection and disseminate to other organs such as the bones,
lymph nodes, the brain, the spinal cord, the skin, the genital tract and the abdomen. It
is important to note that not all carriers of MTB have the disease. According to the
immune response of the host, some of them have active infection as the bacilli can
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stay dormant for years. Malnutrition, poor aeration and low exposure to sun light and
immune-comprising condition as co-infection with other disease like HIV are all
essential factors that can activate the infection [1]. Therefore, TB is more prevalent in
the developing countries where poverty prevails [5]. Limited resources affect
accessibility to effective diagnostic methods and treatment. Also, poor medical
awareness and poverty adversely affect compliance to treatment and thus increase
incidence of drug resistance [6]. In efforts to control the global TB strike, WHO
established the STOP TB program which has several missions in order to eradicate
TB. It prepares road maps for adequate TB diagnosis, treatment and prevention. The
organization main activities were divided into DOTS (Direct observed therapy, short
courses) and research to innovate new drugs and vaccines. DOTS program served 32
million TB patients and contributed to the cure of 28 million people. Their services
are also beneficial for MDR-TB and HIV patients [7]. The TB Research Movement
that was developed by Stop TB Partnership and WHO, recommends the development
of new diagnostic tools characterized by feasibility in limited resource settings, short
turn-around time, cost-effectiveness, availability at the point of care (POC) level,
possible differentiation between different TB forms (drug-sensitive, drug-resistant, or
MDR-TB) and usefulness in pediatric TB patients [8].

1.3. Mycobacterium tuberculosis
The Mycobacterium genus is composed of Mycobacterium tuberculosis complex
(MTBC) members, M. Leprae and non-tuberculous mycobacterium (NTM) [9].
MTBC has 8 members which are MTB, M. canettii, M. africanum, M. bovis, M.
caprae, M. microti, M. pinnipedii, and M. Bovis and the attenuated BCG vaccine
strain. However, only the MTB is the main causative agent of TB and the other
species rarely cause human infection [10]. The name of genus is originated from term
Myco- which means fungus due to their morphology which looks like fibers [11]. It is
cultured on either solid medium as Lowenstein Jensen (LJ) and appears as clusters or
on liquid culture medium (middlebrook 7H9 broth) where the growth is faster and
appears as turbidity. Because the staining by carbol fuschin is not dissolved by acidalcohol, it is called acid fast [12]. MTB bacilli are intracellular gram positive aerobic
non-motile bacteria which infects macrophages [13]. The bacilli (0.5 to 3 µm) are
1

well known by their long duplication time that reaches 20 hours [10,14]. The
morphology of MTB bacilli may vary according to the surrounding media. For
example, the MTB bacilli tend to be oval in shape in case of nutrient deficiency.
Inside the macrophages, they look like fibers. Extreme drug resistant-TB (XDR-TB)
may grow as branched filaments. The cell wall consists of two layers. The outer layer
is composed of several proteins and lipids while the inner one is characterized by the
presence of mycolic acids linked to peptidoglycan and arabinogalactan (figure 4). The
peptidoglycan confers the bacilli its shape [15].
The genome of the reference strain MTB H37Ra consists of more than 4 million base
pairs. It is characterized by the presence of about 200 out of 4000 genes for fat
metabolism only which is considered relatively a high number. This explains the
ability of MTB bacilli to use the host’s cells as the carbon source. MTB does not have
defined virulent factors. However, its ability to live inside the macrophages,
production of certain proteins as katG and SodA which neutralize the toxic secretions
of the macrophages and the rigid lipid rich cell wall (plays a key role in drug
resistance) are the main defense mechanisms [1].

1.4. Pathophysiology of TB
Inhalation of only one to three bacilli is enough to induce infection. After inhalation
of MTB bacilli most of the bacilli are exhaled away but some may sneak to the lower
respiratory tract. The macrophages move to the site of infection and destroy the
bacilli. In case of the failure of the macrophages to terminate the bacteria, the
macrophages engulf the bacilli forming a tubercle where the bacteria remain dormant
then solidifies and appears in chest x-ray. This is called Ghon complex and it is
characterized by its low pH and oxygen deficiency. All these rigid conditions alter the
bacilli replication but do not eradicate them. Moreover, they can stay dormant in these
conditions for years [1, 12]. If the host’s immunity becomes weaker, this granuloma
may soften and the bacteria spread to the lung and other organs as the lymph nodes
resulting in active infection [12].The symptoms of the active disease are vague and
non-specific. They include general fatigue, fever, night sweets and productive cough
with or without hemorrhage, loss of appetite and therefore unexplained weight loss.
That is why this disease is sometimes called “consumption” [11]. If the patient is left
2

untreated, MTB causes suffocation of the lungs by two scenarios: severe destruction
of the lung tissues by decreasing the oxygen supply or granuloma softening which
releases the bacilli. This process induces internal hemorrhage and tubercle formation
which also suffocate the patient (figure 5) [1]. Although the rigid cell wall protects
the bacilli, it is also one of the bacterial virulent factors. The cell wall components of
the MTB are very distinctive due to the presence of glycolipid lipoarabinomannan
(LAM) and lipopeptides [1, 11]. The mycolic acids allocated in a vertical position is
the main bacilli protective shield. Phthiocerol dimycoserate is one of these acids
which is referred by some authors as the wax ball surrounding the bacteria and its
virulence is evidenced by its rareness in the attenuated strains [1]. In addition, the cell
wall morphology is designed to inhibit the host’s enzymatic degradation and
neutralizes the destructive oxygen and nitrogen derivatives and in the same time,
other cell wall components induce alveolar macrophages apoptosis. The phagocytosis
of the MTB bacilli stimulates the secretion of inflammatory cytokines which induces
bronchial inflammation and aids in granuloma development. Moreover, this process
recruits the neutrophilis, monocytes and lymphocytes, which accumulate in the site of
infection and results in bronchoconstriction [11].

1.5. TB Vaccine
In 1920, the BCG was invented from life attenuated M. bovis and is the only available
vaccine. However, its efficiency is variant (0-80%) depending on the immune
response of the vaccinated person. In USA, it is recommended for people at high risk
only [12]. In Egypt, this vaccine is compulsory for all newborns.

1.6. TB treatment
The treatment efficiency is affected by two factors; the bacilli may escape to shield
themselves inside the macrophages so they become unreachable by the antibiotics.
The second factor is the slow growth which alters the effect of the antibiotics because
they are active against the bacteria during the growth. Also, drug resistance typically
develops after prescribing regimens with a single antibiotic [10].
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After reliance on streptomycin to treat TB, the British Medical Research council
reported the first streptomycin resistant cases. It was concluded that multiple
antibiotics should be administered to cure patients. Because rifampicin and isoniazid
are the main drugs against TB, strains resistant to both antibiotics are described as
MDR-TB. In the early 1990s, some countries as USA and Russia had reported high
number of patients infected with resistant TB. Shortly, these reports were received
from several other countries [6].
TB is defined as MDR-TB when it resists at least rifampicin and isoniazid [16, 17].
When the bacteria resist antibiotics from the first line and second line, it is called
extreme drug resistant TB (XDR-TB) which will lead to patients’ death due to lack of
treatment [14].
The bacterial strain is called resistant when at least 1% of the bacterial population
resists the antibiotic [18]. Primary resistance is when the patient is infected with a
resistant strain and secondary which is more common, when the patient is infected
with susceptible strain but due to inadequate treatment, the bacteria resist the drugs
[14]. The anti-tuberculous drugs are divided into two categories; first line (table 1)
and second line antibiotics.

1.6.1. First line antibiotics
Rifampicin is an essential anti-tuberculous drug which inhibits the transcription of the
β-subunit of the RNA polymerase. Most of rifampicin resistant strains have mutations
in the 81-bp region of the rpoB gene which is called Rifampicin ResistanceDetermining Region (RRDR) which are present in codons 507 to 533 [16, 17, 19].
The rpoB gene is the encoding gene of the β-subunit of RNA polymerase; a tetra
subunit enzyme consists of α, β, β’ and δ subunits. In addition, according to the
mutation site, the resistance degree varies. Mutations in amino acid 526 and 531 result
in high resistance while in 511, 516, 519 and 522 result in weaker resistance (MIC
below 64 µg/ml). There is still probability of other mutations in the terminal amino
acids and need for advanced tests in case of negative result of drug susceptibility test
[15]. Isoniazid is the second main anti-tuberculous drug which is a prodrug activated
in the human cell by bacterial catalase peroxidase. The bacteria resist this drug by
4

mutations in the enzyme encoding gene (KatG) to decrease its production. The
mutations occur mainly in KatG, inhA genes and inhA promoter. Inside KatG only,
there are several possible mutations and is responsible for 50-90% of isoniazid
resistant cases. Mutations in other genes are proved to be responsible for isoniazid
resistance as KasA, aphC and ndh. Resistance to isoniazid is most probably coupled
with rifampicin resistance [15, 16]. Pyrazinamide is a prodrug used to treat TB
activated by the enzyme pyrazinamidase in vivo [6, 15]. The bacteria resist it by about
120 different mutations in pncA gene. By molecular techniques, line probe was able to
detect all these mutations accurately. However, testing the bacterial susceptibility by
culture is not easy because the drug is active at acidic pH which inhibits the bacterial
growth [15]. Ethambutol is activated in vivo and inhibits the attachment of the
mycolic acids to the cell wall [6]. Resistance to it develops due to mutations in embB
gene especially in codon 306 which represent 47-62% of the resistance cases. Other
mutations in codons 330 and 630 result in ethambutol resistance as well.
Streptomycin is an aminoglycoside antibiotic and is considered as second line in some
references. Mutations in the genes rrs and rpsL are the common reason to develop
resistance to streptomycin. However, other mutations in other genes can also cause
resistance. Till now, there is no rapid method to test the susceptibility of tuberculosis
to streptomycin [15]. Drug resistance mutation(s) are summarized in (table 2).

1.6.2. Second line antibiotics
Fluoroquinolones, ethionamide and aminoglycosides as amikacin and kanamycin are
all active antibiotics against TB [15]. The first line antibiotics are preferred because
cure can be achieved after 6 months while when administering second line antibiotics,
the treatment duration will extend to at least 18 months with less efficiency and more
adverse effects [20].

1.7. TB diagnosis
Early diagnosis of TB is necessary to eliminate inhalation transmission, prevent
development of resistance and subsequently reduces death rate from this disease
especially among HIV co-infected patients [21]. Despite the need for accurate
5

diagnosis of TB, sometimes presumptive diagnosis is done according to the patient’s
history and confirmed by smear microscopic testing and/or radiological findings [22,
23]. Also drug susceptibility testing (DST) is not performed until the treatment by the
first line antibiotics fails or the patient has recurrent TB infection [24]. Timely TB
diagnosis and drug susceptibility testing using culture-based methods are limited by
the slow growth of the bacilli. Culturing the bacteria, determine whether it is typical
or atypical and DST need weeks to perform. Moreover, positive results need rigid
confirmation [6].
Further differential testing is now needed due to increase in NTM infections that
cause similar clinical symptoms to that of MTB. NTMs were considered opportunistic
infection until the breakthrough of HIV which increased incidence of NTM
pulmonary infection [25, 26]. The essentiality of differentiation of Mycobacterium
infections arises from the difference in the drugs regimens used to treat NTM [27].
All the diagnostic procedures are summarized in table 3.
WHO strongly recommends that the governments of the high burden countries should
participate by a great impact to achieve the goals of END TB program. This program
is launched by the WHO and has four main activities: early diagnosis of TB and DST
in addition to regular screening of high risk people, treatment of patients carrying
drug susceptible and resistant strains, co-operation with HIV programs and finally
prevention of new infections and vaccines development [24].

1.7.1. Specimens collection and preservation
Enough sputum should be expectorated by the patients. Some patients as the
pediatrics and HIV patients have low sputum volume and/or low bacterial load in
their sputum. Saline spray aids to increase the specimen volume but the patients need
assistance to use it. The specimen collection and preservation importance arises when
it is not analyzed on time or needs to travel for further investigation. The lung flute
(Medical Acoustics, New York, USA), which is FDA approved, helps the patients to
collect the sputum in-house. It is held by the patient’s mouth and stimulates the lung
to soften and expectorate the sputum. The second product is produced by Deton Corp.
(Pasadena, USA) which is a big bag in which the patient coughs. It collects the
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bacilli-containing droplets and the air is pulled out physically. After specimen
collection, the second step is the preparation of the sample. OMNIgene SPUTUM
(DNA Genotek Inc., Ottawa, Canada) produces a liquefaction, decontamination and
preservation system for the samples without the need for freezing up to 8 days. The
samples did not have any contamination when investigated on LJ media [24].

1.7.2. Microscopic observation
The first line diagnostic method for MTB is smear microscopy which is 125 years old
[12, 28]. It relies on staining of the acid fast bacilli using Ziehl Neelsen (ZN) stain
(figure 6). It is fast and cheap so used heavily in poor-resources countries for TB
diagnosis and monitoring the patients receiving anti-tuberculous antibiotics. With
accuracy varying from 35% to 80%, additional diagnostic method must ascertain the
negative sample because only one bacillus in the sample is enough to call the sample
positive. However, 5,000 bacteria/ml are required to be present to allow bacilli
detection by smear microscopy. Despite the great danger of TB spread from patients
of high bacterial load, 17% of the misdiagnosed patients by smear microscopy due to
their low bacterial load transmit the bacilli to their surrounding community [29]. So
the false negative results are found among HIV patients and extra pulmonary TB
patients. Also, it does not give information about the bacterial type, its activity and
drug susceptibility [30]. It is useful to indicate active infection as only viable cell will
retain the stain while the dead bacilli have leaking cell wall which won’t retain the
stain. Smear microscopy is recommended for the diagnosis of pulmonary TB with
minimum of two sputum samples collected in two successive mornings. The
sensitivity of smear microscopy can be enhanced by concentrating the sputum
samples. However, this process needs sophisticated biosafety concerns for the
working technician in addition to the long time consumed [3, 31]. The introduction of
the fluorescence dyes to stain the MTB bacilli and the use of the fluorescent
microscopy (FM) enhanced the sensitivity by 10%. Even sample preparation and
examination extended for shorter time and allowed to increase the number of
examined samples per day. The spread of the FM in peripheral laboratories was
altered by the high cost of the bulb and the need for regular maintenance. The use of
the potent light emitting diode (LED) allowed the spread of FM after replacing the
bulb in peripheral laboratories due to its powerful light, lower cost, longer life time of
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the bulb and elimination of the risk of exposure to mercury vapor in case of bulb
breakage. WHO recommends the replacement of FM by LED microscopes for smear
microscopy. The automated microscopy allowed the accurate screening of the
fluorescent bacilli after manual preparation of the slides. They are accompanied by
software that analyzes every field in the slide and needs only five minutes for
complete slide analysis. This microscope dispensed the usage of Xpert MTB/RIF
(NAAT diagnostic tool recommended by WHO and discussed alter) by 73% for TB
diagnosis. Becton Dickinson Corp. (New Jersey, USA) also developed an automated
system that stains the TB smears and analyzes them. its performance is nearly similar
to LED-microscope [24]. WHO recommends the testing of the smear microscopy by
the conventional or LED microscopy in the peripheral laboratories [29].

1.7.3. Digital chest X-ray
Digital chest X-ray allows detection of MTB in resources limited settings
recommended by the WHO. It is rapid and accurate even in HIV co-infected patients.
Delft Imaging Systems (Veenendaal, Netherlands) developed the software CAD4TB
to analyze the images to detect any lung abnormalities (figure 7) [24].

1.7.4. Biomarkers based MTB detection

1.7.4.1. Chromatographic detection of MTB
Determine™ TB LAM Ag (Alere Inc., Waltham, Massachusetts, USA) is an
immunochromatographic strip that detects the LAM which is a MTB glycolipid
present in the living and disseminated bacilli. LAM is detected in the urine and is
useful for the detection pulmonary and extra pulmonary TB and NTM. Recent studies
reported that this assay is a useful indicator for severe infection in HIV patients [24,
29].

1.7.4.2. Volatile organic compounds (VOC) for detection of MTB
When TB infection is active, oxidative stress products, volatile compounds and nitric
oxide are present in the patient’s breath. The detection of these volatile compounds
offers a non-invasive screening for TB patients [29]. TB Breathalyzer (Rapid
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Biosesnsor Systems Ltd, UK) is an example device that detects these VOC by just
coughing in a certain device and the result is available within 4 minutes.

1.7.5. Immuno-response based assays

1.7.5.1. Tuberculin test
It is the injection of low concentration of TB antigen (protein purified derivative)
subcutaneously. After 48 hours, the injection site becomes red due to immune reaction
to the antigen (figure 8). The positive result in youth is most probably active
infection. While in elderly, it may indicate latent infection or vaccination. After this
test, chest x-ray, microscopic examination of sputum samples, culture and molecular
diagnosis should be performed. The main drawback is the inability of the test to
differentiate the active from latent infection and from BCG vaccine [12, 29].

1.7.5.2. Serological assays
These assays detect MTB indirectly through capturing the anti-tuberculous antibodies.
ELISA and LAM-ELISA detect LAM. However, The WHO recommendation is to
avoid using the blood but use the urine to diagnose TB either pulmonary or extrapulmonary. The assay also can’t differentiate between the viable and dead bacilli. The
sensitivity for pulmonary and extra-pulmonary TB was 65% and 55% respectively.
Serological test costs about $30 per sample and there is high possibility of false
negative results [32]. Because the commercial serological tests detect the antibodies,
they do not differentiate between recent and old infection or even between infection
and vaccination [29]. TB Interferon-Gamma Release Assays (IGRAs) are other
example of serological tests that detect the γ-interferon released by the white blood
cells of the infected people. Due to its poor sensitivity, it does not distinguish between
active and latent infection. WHO recommends it only in poor resource countries [33].

1.7.6. Bacterial culture
According to the WHO protocol, smear microscopy and culture are done from sputum
collected in the early morning from 3 consecutive days. Decontamination of the
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sputum is a primary step. It is always done by the traditional NAOH-N-acetyl cysteine
based method. A recent kit called Decomics (Salubris Inc., Massachusetts, USA)
utilizes beads of high absorption capacity and specific chemicals for proper
decontamination of sputum [29]. Culture is the second step in the diagnosis and it is
considered the gold standard method for both MTB detection and DST. Several solid
culture media are used for isolation, identification, species differentiation and DST as
Lowenstein-Jensen (LJ), middlebrook 7H10 and blood agar. However, due to the slow
metabolic activity of MTB, species identification and DST require several weeks to
obtain conclusive results which extend to 2 and 6 weeks for liquid and solid culture
medium, respectively [29]. The sensitivity of the culture is 100 bacteria/ml. The
culture doesn’t allow differentiation of MTB from NTM by initial culture because the
colonies morphology is nearly identical [29, 34, 35]. The essentiality of species
differentiation comes from the presence of inherently resistance for specific
antibiotics. For example; M. bovis, BCG, and M. canettii have innate resistant to
pyrazinamide [36, 37]. Molecular assays, biochemical tests or additional culture for 2
to 4 weeks are recommended for species discrimination [38, 39]. For example, LJ
medium containing glycerol is used to allow the growth of MTB and inhibits the
growth of M. bovis. When isolation of M. bovis is required, pyruvate is added to the
culture medium instead of glycerol [40, 41]. Several improvements have been
introduced to benefit from the sensitivity of the culture and overcome the drawback
which is the long duration. Microscopic observation drug susceptibility (MODS)
involves the microscopic examination of the liquid culture media (middlebrook 7H9)
by inverted light microscope and the duration of the test is 9 days. MODS is used for
MTB differentiation from NTM by the addition of para-benzoic acid which inhibits
the growth of MTB only. The incorporation of antibiotics to the culture media was
exploited to perform DST by MODS [29, 42]. Also the growth patterns differ
according to the species so differentiation was allowed by MODS [43]. Culture-based
DST is performed by several assays as nitrate reductase and colorimetric redox
indicator (CRI). All these methods are based on culturing bacteria on drug-containing
culture media. The color change indicates the ability of the resistant bacteria to grow
in the presence of the antibiotic of interest and to perform certain reaction indicating
the presence of resistant strains. Although the accuracy of these methods reaches
99%, the long time to obtain the results which extends to 2 weeks limits their
application [44-48].
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Another type of the liquid culture is the automated liquid culture. A famous example
is Bactec 960 MGIT (Beckton Dickson) which is enriched by oleic acid, albumin,
dextrose and catalase to enhance the MTB bacilli growth. Drugs as polymyxin B,
amphotericin B, nalidixic acid and trimethoprim are added to prevent contamination.
The growth of MTB bacilli is hastened to about 7 to 10 days and the growth is
detected by either colorimetric or fluorometric detection. Species differentiation and
DST can also be performed. However, this method needs expensive instruments and
trained personnel. In addition, the problem of radioactive waste products is an issue
[3, 29]. WHO recommends performing the culture including the MODS, CRI and
nitrate reductase in the reference laboratories only [29].

1.7.7. Nucleic Acids Amplification Techniques (NAATs)
For tuberculosis to be detected by molecular test, the bacteria should disseminate to
the blood stream, urine, sputum and the affected organs. Molecular assays allow
detection of MTB in clinical samples, differentiation of MTB from NTM, DST and
performing epidemiological studies. The results are reproducible when the sample is
smear positive and accuracy reaches more than 95%. It saves the costs of isolation of
patients suspected to have be infected with MDR-TB or XDR-TB and cost saving is
up to $15,000 per year [49, 50]. However, in some cases as extra pulmonary TB,
culture is needed before performing the NAATs to increase the amount of the DNA
[27].
Polymerase chain reaction (PCR) and isothermal amplification are the most common
approaches of amplification of nucleic acid. Although the performance time extends
to 8 hours, NAATs are much faster than culture. So these tests are the most beneficial
in life threatening cases as meningitis MTB where smear microscopy is not suitable
and the culture time can be too long to save the patient’s life [29]. Despite the
development of many molecular techniques as commercial kits and in-house assays,
LPAs (Hain Lifescience, Nehren, Germany); INNO-LipA (Fuji-Rebio Europe,
Göteborg, Sweden); and Xpert® MTB/RIF (Cepheid, California, USA) are the only
WHO approved molecular assays to detect MTB [24]. WHO recommends the
molecular tests for smear positive samples when the patients had not administered any
antibiotics (the first sample or the first smear positive sample are the suitable
samples). The sensitivity is 95% and the specificity is up to 100%. However, they are
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recommended when the sample is smear and culture positive. While the sensitivity
drops dramatically when the smear is negative and the culture is positive for the
following reasons. The number of the bacteria is very few and the DNA extraction is
faced by the strong cell wall of the bacteria. A recent study evaluated Amplicor-MTB
(Roche, Risch-Rotkreuz, Switzerland), BD Probe (Becton Dickson) and transcription
mediated amplification; the sensitivity was about 97% although the specificity varied
from 71% to 96% for smear positive/culture positive samples. However, for smear
negative/culture positive samples, the sensitivity ranged from 57% to 76%. Moreover,
factors as the type of the sample and storage, the DNA extraction and amplification
protocol, the visualization method of the hybridization and the presence of any
inhibitors or contaminants will affect the accuracy [10]. So these tests are useful to
confirm infection rapidly. Also, these assays require complex infrastructure for DNA
extraction and test performing. The personnel should also be well-trained and work
according to standard procedures. The risk of contamination can be overcome by the
use of automated systems. However, the cost will be high due to the regular
maintenance and the required reagents. Despite the presence of several assays, the
lack of standardization limits their approval by the FDA. So till now, the gold
standard methods for TB diagnosis are the smear microscopy confirmed by culture,
and selective culture for DST. The diagnosis of TB patients co-infected with HIV,
pediatric TB patients and extra pulmonary TB by sputum samples needs further
investigation [29]. Despite the great sensitivity of molecular assays, the culture is still
the most sensitive diagnostic tool. Most NAATs tests can’t detect TB in blood
samples. They can’t be used to monitor the effectiveness of the therapy as the bacteria
will be detected whether alive or dead [51]. One study revealed positive PCR results
from patients successfully cured 2 years ago [52].
Sequencing of the 16s rDNA and 16S-23S internal transcribes spacer (ITS) is
considered one of the most accurate detection methods for MTB [9, 25, 53]. The
sequence of this region varies from 270 to 360 bp according to the species and thus
amplification of this region followed by sequencing allows species differentiation
[54]. The sequence of interest is compared to libraries as Genbank, the Ribosomal
Differentiation of medical Microsystems databases and European molecular biology
laboratory [9]. Comparison between commercially available NAATs for MTB

detection is presented in table 4. The pipeline of NAATs for TB diagnosis is
illustrated in table 5.
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The variable region 16s rDNA is one of the most common sequences to target [55].
The gene 16s rDNA has 1500 bp. However, the first 500 bp are conserved among all
MTB strains. So sequencing allows the exploration of unknown species [9]. Also
IS6110 which is a non-coding insertion sequence is used frequently for direct
detection of MTB due its repetition up to 25 times in the whole genome and was
detected by several primers from sputum samples [22, 56]. Specific targets within
rpoB gene are widely applied to allow detection of MTB DNA and differentiate it
from other mycobacterium. According to the primers, the rpoB gene is used either to
detect MTB or to detect mutations responsible for rifampicin resistance [16, 18].
Targets within other genes as gene of 32, 38 or 65 KD protein, recA , hsp65, dnaJ,
sodA and 16S-23S rRNA, , groE1, or mtb-4 genes are also used to detect MTB [9,
29]. WHO recommendations about NAATs are in table 6.
1.7.7.1. Automated MTB detection assays
COBAS® TaqMan® MTB (Roche Diagnostics) investigates 44 samples in the same
time by the real time PCR. Liquefaction, decontamination and concentration of the
sputum or bronchial lavage sample are a must before performing the assay. It detects
the 16S RNA by real time PCR and the data is interpreted and stored automatically.
The sensitivity is 96.4% for smear and culture positive specimens and drops to 76.8%
for smear negative/culture positive. The detection limit is 18 bacilli/ml. Molecular
Realtime MTB (Abbott, Chicago, IL, USA) is another assay that detects MTB DNA
from NAOH-N-acetyl-L-cysteine treated sputum or bronchial lavage specimens.
DNA extraction can also be automated. The operation time to extract and analyze 94
samples (its capacity) extends for 7 hours. The detection limit is 17 bacilli. The
sensitivity is 97% for smear and culture positive and 81% when the smear is negative.
Due to the cost of the device, its wide usage is limited in the resource-limited
countries. An automated assay that detects MTB DNA by molecular beacons is
Fluorotype® MTB (Hain Lifescience). The DNA is amplified with the molecular
beacons and the fluorescence is detected by specific software. Smear/ culture positive
and smear negative/culture positive are diagnosed by sensitivity 100% and 90%
respectively. This assay is also developed to detect MDR-TB. BD MAX™ platform
(Becton Dickinson) which is still under development, utilizes real time PCR to detect
MTB and to identify MDR. Its performance capacity is 24 samples in each run [24].
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1.7.7.2. Autonomous MTB detection assays
These assays are not automated so they require the usage of several devices,
complicated

infrastructure

and

trained

personnel.

The

Anyplex

(Bio-Rad

Laboratories, Hercules, California, USA) utilizes multiplex PCR to detect MTB,
investigate MDR-TB and XDR-TB. The primers are designed by specific software
and sample preparation should be performed before using this assay. The second
example is MeltPro® Drug-Resistant TB Testing Kits (Xiamen Zeesan Biotech Co.
Ltd, Hong Kong, China) that detects point mutation of rifampicin and isoniazid by
real time PCR. Further development are done to achieve the detection of ethambutol,
streptomycin and fluoroquinolones resistance [24].

1.7.7.3. Line probe assays
GenoType® MTBDRplus (Hain Lifesceince) and INNO-LipA Rif.TB (Fuji-Rebio
Europe) were the first assays approved by WHO for MTB and MDR-TB detection.
They also allow species differentiation from NTM and investigate resistance to first
line and second line antibiotics. Their costs are affordable for the high burden
countries. The samples should be DNA extracted from culture and amplified to attach
biotin and immobilized on nitrocellulose. The probes are attached to streptavidinbound enzyme that allows colorimetric interpretation of the results which are then
analyzed by certain software [24].

1.7.7.4. DNA microarrays
DNA microarrays depend on determining sequences within the 16s rRNA by
fluorescence-labeled probes. The intensity of the fluorescence is proportional to the
hybridization pattern and is measured by fluorescent microscopy. The results are
available within few hours [10]. They are considered simplified form of line probe
assays. The Autogenomics INFINITI® PLUS Analyzer platform (AutoGenomics,
Vista, USA) is approved by FDA and can test 48 samples in 3.5 hours. The MTB
Identification Array Kit (CapitalBio, Beijing, China) is used for MTB detection and
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differentiation. The M. Tuberculosis Drug Resistance Detection Array Kit
(CapitalBio) is used for MTB detection and identification of rifampicin and isoniazid
resistance. TruArray® MDR-TB (Akonni Biosystems, Frederick, USA) is another
microarray test that detects MTB and differentiates it from M. avium by using
multiplex PCR to amplify the DNA and the fluorescence is detected by TRUdiagnosis
software. VereMTB™ Detection Kit (Veredus Laboratories, Singapore) contains 500
probes by which it identifies the MTB through targeting the IS6110 and 16S RNA,
allows species differentiation from 8 NTM species and identifies rifampicin and
isoniazid associated mutations [24].

1.7.7.5. Modular, cartridge-based, fully automated NAAT
Xpert® MTB/RIF (Cepheid Inc.) is the only NAATs diagnostic assay approved by
WHO for MTB detection [24]. Performing the test takes about 2 hours with only one
step done manually and the reagent can be kept at room temperature for one and half
year. The assay detects MTB and rifampicin resistance accurately especially when the
sample is smear and culture positive [24, 29]. It has modules for sample preparation
and semi-nested PCR of rpoB for investigation of rifampicin resistance. WHO
recommends its use for the diagnosis of suspected MDR-TB, HIV patients and for TB
meningitis diagnosis [24].

1.7.7.6. Semi-automated NAATs
Eiken’s Loopamp™ (Eiken Chemical Co. Ltd, Japan) MTB kit detects MTB from
sputum samples without any pretreatment in the lysis tube by loop mediated
amplification. Heating is used for MTB bacilli lysis [24]. It is an isothermal
amplification assay which depends of amplification only of the target sequences when
present. The hybridization action is investigated by gel electrophoresis to ensure the
formation of the DNA target size. Also the double strand binds to SYBR green dye
and the solution becomes green. However, when the target sequence is absent, the
color of the solution remains orange. In both case, screening by ultraviolet is done
[29].
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1.7.8. Detection of TB by phage-display
The concept of these detection approaches is the use of a specific phage that infects
only viable MTB bacilli. The number of phages is proportional to the number of
bacterial cells. The sensitivity and specificity for smear positive are 87% and 88% and
for smear negative/culture positive are 67% and 98%. The test needs 2-3 days to get
results and is considered a cheap diagnostic method. The available test in the market
is FASTPlaque TB assay (Biotic laboratories Ltd., Ipswich, UK). Another assay is
Phage amplified biological assays (Pha B) which utilizes the mycobacteriophage D29
detects the bacteria in only 24 hours. However, the sensitivity is only 31%. The Phage
Tek MB assay (Organon Teknika, Durham, NC, USA) is also available in the market
but its low sensitivity limits its use. Another assay utilizes a phage that translates the
luciferase enzyme. When the phage infects the bacteria, it oxidizes luciferin using
ATP. Light is generated indicating the presence of viable mycobacteria so this assay
can also be used to test the susceptibility of the bacteria. The light intensity is
measured by a luminometer and results are generated within 2 days [9, 29].

1.7.9. Detection of TB by nanoparticles

1.7.9.1. Gold nanoparticles (AuNPs)
Spherical AuNPs has average size from 0.8 to 250 nm. The large volume: surface area
ratio is responsible for the activity of AuNPs where the bulk gold lacks this property.
AuNPs are widely used due to their Surface Plasmon resonance (SPR) which results
from the collective oscillation of the electrons of the conduction band (figure 9). This
gives the solution its red color and the absorption peak is at 520 nm for 20 nm AuNPs.
The solution of the AuNPs turns blue upon their aggregations which red shits the
absorption to 620 nm due to plasmon coupling of the aggregated AuNPs. This
sensitivity is widely exploited to detect biological molecules as antigens, antibodies
and DNA sequences [28, 57]. In addition, AuNPs are biocompatible so they are
suitable for biological application. They can be manipulated to display several
properties based on their particle size, surface charge, shape and inter-particle spaces
[53]. The diversity of the AuNPs size and morphology allowed their use as scaffolds
for the development of innovative assays platforms. The introduction of the AuNPs as
fluorophore’s quencher was investigated 40 years ago. Fluorescence resonance energy
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transfer (FRET) technology is defined as spectroscopic approach to measure distances
in the range of 30-80 A° [58, 59]. AuNPs can absorb excitation energy from several
dyes in the same time [60]. The donor particle (dye or the fluorophore) is excited by a
certain wave length and this excitation energy is transferred to the acceptor (AuNPs)
(figure 10). This non-radiative energy is dependent on the space between the donor
and the acceptor [58, 60, 61]. The rate of the energy transfer is inversely proportional
to the sixth power space between the fluorophore and the quencher [62]. Recently, the
application of AuNPs as fluorescence quencher is useful for disease diagnosis by
capturing a specific DNA sequence by its complementary probe. Because the
hybridization energy is 80 kcal/mol and extremely exceed the adsorption energy of
the fluorophore on the AuNPs surfaces (8-16 kcal/mol), the DNA probes favors the
hybridization with their complementary targets [58, 62]. Absorption was found to be
the prominent behavior of 40 nm AuNPs. Larger particles were found to enhance the
fluorescence by scattering [59]. The factors affecting the non-radiative energy transfer
between the AuNPs and the fluorophores are the morphology and the diameter of the
AuNPs, the distance spacing the AuNPs from the fluorophore and the intersection of
the emission of the fluorophore and the absorption of the AuNPs [63]. Several
diseases were accurately diagnosed by FRET technology by detection of the DNA
such as herpes simplex, Gilbert’s syndrome, parasites as malaria and toxoplasmosis,
fungal infection as invasive aspergillosis and candidiasis [64-66].

1.7.9.1.1. AuNPs synthesis
AuNPs synthesis is attempted by either top-down or bottom up pathway. The first
pathway means the synthesis of AuNPs from bulk particles. The second pathway
which is more common allows the AuNPs to grow from the corresponding chemicals
and the size is controlled [67]. The gold salt is dissolved in a suitable solvent and
reduced to its ground valence state by a reducing agent as the citrate which also
stabilizes the AuNPs by prohibiting their aggregation. By controlling the reaction
parameters which are the reducing agent type and concentration, time and
temperature, the desired morphology and size of the AuNPs is achieved. The simple
citrate reduction method was introduced 65 years ago [68]. The synthesis is
performed by reducing the gold derivative (gold (III) chloride trihydrate) to Au0 by
sodium citrate dibasic trihydrate. The citrate can be replaced by another reducing
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agent according the AuNPs of interest [68, 69]. When thiolated AuNPs are desired to
by synthesized, Shiffrin method is followed [68]. The affinity between the gold and
thiol is exploited to stabilize the gold by an alkenthiol as DDT (dodecanethiol) and the
reduction is performed by sodium borohydride in dissolved in toluene. The thiolated
AuNPs can be functionlized through antigen- antibody or streptavidin-biotin linkage
with thiol groups. These particles are manipulated to allow detection of antigens,
DNA specific sequences, peptides or carbohydrate [67-70].

1.7.9.1.2. Modified AuNPs for MTB detection
Thiol groups attached to the oligonucleotides and hence allow the binding of the
AuNPs. If the target is present in the sample, the complementary sequences will
anneal and AuNPs become free and aggregate in the presence of NaCl. The
aggregation induces color change from red to blue due to the SPR of the AuNPs. Soo
et al, developed AuNPs based assay to detect MTB by targeting IS6110 and Rv3618
with amplicons of nested PCR and double probes specific for each target. The probes
were linked to thiolated AuNPs and hybridization with complementary DNA
sequence in the positive samples induced the visible color change from red to violet
due to the shortening of the inter-particle space of the AuNPs. MTB and MTBC were
detected with 96.6% sensitivity and 98.9% specificity, and 94.7% sensitivity and
99.6% specificity, respectively [71]. Baptista et al, detected MTB DNA from clinical
samples targeting the rpoB region. The detection limit was 0.75 µg [72]. Costa et al.
developed another AuNPs based assay to detect MTBC and differentiation of MTB
from M. bovis. Specific probes targeting the gene gyrB were allowed to hybridize
with the amplified DNA [73]. Liandris et al. targeted 16S- 23S ITS using AuNPs
modified probes specific for MTB. Unamplified DNA was detected with detection
limit of 18.75 ng [74]. Das et al, developed AuNPs based biosensor by
depositing zirconium oxide linked to MTB specific probe on gold surface. The probe
was linked to the zirconium by exploiting the affinity between the oxygen atom of the
phosphate backbone of ssDNA and zirconium atoms. The detection limit of the
biosensor was 0.065 ng/µl. [75].
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1.7.9.1.3. Unmodified AuNPs for MTB detection
Thiolated AuNPs synthesis needs long time and is relatively cumbersome [26]. So the
use of unmodified AuNPs saves the time, effort and cost of surface
biofunctionlization. Hussain et al. detected MTB using 16s rDNA specific
oligotargeter. Amplified and genomic MTB DNA were detected successfully and the
sensitivity was 100% compared to genus and species specific semi-nested PCR [55].
Tsai et al, used unmodified AuNPs to detect amplified DNA by targeting IS6110. In
case of positive samples, the probe hybridized with its target and the resulting charge
of dsDNA was negative. The repulsion between the dsDNA and the negatively
charged AuNPs resulted in AuNPs aggregation the color was changed from red to
blue. If the target DNA is absent, the DNA probes would remain attracted to the
AuNPs and prevent their aggregation and consequently, the color of the solution
remained red. The detection limit for this assay is 2.6 nM [26]. The characteristics of
the previous assays are compared in table 7.

1.7.9.2. Detection of TB by FRET
FRET-based detection of TB and drug resistance mutations were investigated by
several research groups. Hwang et al. used upconversion nanoparticles (UNNPs)
made of rare earth lanthanide elements. The assay depends on biotinylated PCR
amplification of the IS6110 sequence of MTBC, mixing with the UCNPs conjugated
with streptavidin (FRET donor) and addition of SYTOX orange dye that is
intercalated in dsDNA (FRET acceptor). The decrease in green fluorescence of the
UCNPs reports the presence and hybridization of the biotinylated PCR amplicon
(IS6110) to the streptavidin activated UCNPs [76]. Another research group designed
an assay that involves sandwich-form FRET for detection of the MTBC using
cadmium telluride quantum dots (donor) and AuNPs (acceptor) that are both coupled
to different oligonucleotides. The target region is the early secretory antigen target-6
(ESAT-6) DNA which is conserved among all the MTBC members and is not present
in M. bovis so allows differentiation of infection from vaccination [77]. Isoniazid
resistance has been also investigated by FRET. Saribas et al. used real-time PCR and
labeled probes to detect single nucleotide point mutations in the genes inhA, KatG and
ahpC because they are known to involve the mutations responsible for isoniazid
resistance. Two labeled probes were used: one is short probe (sensor) that hybridizes
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at the site of mutation of interest and the longer probe (anchor) hybridizes next to it.
When both probes become in close proximity, high fluorescence is observed. Gradual
increase in the temperature is applied until the sensor probe is not attached anymore
and a massive drop in the fluorescence is observed. The temperature at which the
probe is detached is called the melting temperature. Discrimination between INHsusceptible from resistant strains is allowed because the resistant strains have a
different melting temperature different than the wild strains [78]. El-Haji et al.
detected all the rifampicin associated mutations in the rpoB gene in a single assay
using wave length shifting molecular beacons. The MTB DNA was extracted from
sputum samples, detected by amplifying 16s rDNA region for species differentiation
then the 81-bp region within the rpoB gene was amplified with specific primers. The
amplicons are allowed to anneal with five beacons linked to five different
fluorophores. Each molecular beacon is complementary for a certain mutation site. In
case of the presence of any mutation, the molecular beacon won’t be able to hybridize
and the fluorescence will not appear. Subsequently, only the wild type MTB will emit
the five fluorescence colors. The molecular beacons were modified to be wave length
shifting to allow the emission of longer wave length and better discrimination among
the five fluorophores [79]. Qin et al, detected the MTB bacilli through fluorescent
silica nanoparticles and SYBR- green attached to anti-tuberculous antibodies. The
specific antibodies attach to the bacilli and the double emission of the two dyes
indicates the presence of MTB bacilli [62]. Ekrami et al, used mouse monoclonal
antibodies linked to silica fluorescent nanoparticles for direct detection of MTB
bacilli from sputum samples. The anti-tuberculous antibodies are attracted to the
surface antigens of the MTB and intense fluorescence was observed [80]. The FRET
based assays are illustrated in table 8.
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1.8. Thesis scope and objectives

1.8.1. Development of colorimetric nano-sensor for detection of MTB DNA using
cationic AuNPs.

1.8.2. Development of AuNPs-based FRET sensor for the fluorometeric detection of
MTB DNA.
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Chapter 2: Materials and Methods
2.1. Clinical bacterial strains
This study was performed after getting IRB approval from the American University in
Cairo case #2014-2015-149 and the approval of the Egyptian Ministry of Health No.
2-2015/1. Seventy two anonymous mycobacterial samples from the Central
Laboratories archive were used in this study (figures 11, 12). The geographic
distribution was 24 patients from Abassia Chest Hospital, Cairo governorate, 15
patients from Giza Chest Hospital, Giza governorate, 13 patients from Alexandria
Governorate, 11 patients from Dakahlia Governorate, 2 patients from Suez
Governorate, 2 patients from Helwan City, 1 patient from Matarai City, 1 patient from
Isamlia Governorate, 1 patient from Elmenya Governorate and 1 patient from the
Central Laboratories of Ministry of Health.
All the samples were cultured on LJ liquid medium according to the manufacturer’s
protocol. The culture is done from early morning sputum samples of the Egyptian
patients from different regions all over Egypt. The patients were diagnosed to be
infected with Mycobacterium. None of the samples were known to be whether typical
or atypical Mycobacterium. Reference bacterial strains include M. tuberculosis
H37Ra (positive reference strain) and Mycobacterium smegmatis (negative reference
strains). Four E.coli samples, Acinetobacter baumannii ATCC 17978, Pseudomonas
aeruginosa ATCC 27853, Klebsiella pneumonia ATCC 23495 and Enterobacter
aerogenes ATCC 13048 were the negative samples.

2.2. DNA extraction
Extraction was performed using QIAamp DNA mini extraction kit (Cat no. 51304,
Qiagen, Hilden, Germany). According to the extraction protocol of gram positive
bacteria, cell wall lysis is required prior to extraction. It is accomplished by adding the
bacterial pellet to lysozyme enzyme 20 µg/ml (from chicken egg white, cat no. 41800,
Norgen Biotek Corp., Thorold, Canada) dissolved in 20 mM Tris- Hcl, PH 8 (cat. no.
10812846001, Sigma Aldrich, Missouri, USA), 2 mM EDTA (cat. no. 431788, Sigma
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Aldrich) and 1.2 % triton (cat. no. x100, Sigma Aldrich) and incubated for 30 min at
37 ºC. Then the extraction protocol for gram positive protocol is followed according
to the manufacturer’s protocol. Extraction of the DNA from the gram negative was
done according to the manufacturer’s protocol.

2.3. Identification of the bacterial strains by PCR

2.3.1. Species differentiation using Multiplex PCR
Identification of the samples (n=72) to differentiate MTB from NTM was achieved by
multiplex PCR. Two sets of primers targeting the rpoB region were used [30]. All the
primers are manufactured by BioBasic, Markham, Canada. The primers and the
amplicons size are illustrated in table 9. The reaction mixture volume was 20 μl and
prepared by mixing 10 μl master mix (cat. no. RR310A, Takara Bio. Inc., Shiga,
Japan), 0.75 μl of each primer type from stock concentration 10 μM, 2 μl of DNA
samples and 5 μl of nuclease free water (NFW). The reaction conditions are
denaturation for 3 min at 95 °C and 1 min at 97 °C, 2 cycles for 1 min at 95°C, 30 sec
at 64 °C and 1 min at 72 °C, 2 cycles for 1 min 95 °C, 30 sec at 62 °C and 1 min at 72
°C, 2 cycles for 1 mi at 95°C, 30 sec at 60 °C, 1 min at 72 °C, 2 cycles for 1 min at 95
°C, 30 sec at 60 °C and 1 mi at 72 °C, 2 cycles for 1 min at 95 °C, 30 sec at 58 °C and
1 min at 72 °C, 22 cycles for 1 min at 95 °C, 30 sec at 56 °C and 1 min at 72 °C and 1
cycle at 72 °C for 10 min [30]. The PCR reaction was done using the thermal cycler
(Veriti, Applied Biosystems CA, USA). All the amplicons were examined on 1.5%
w/v agarose gel electrophoresis stained with ethidium bromide.

2.3.2. Amplification of 16S-23S ITS and Sequencing
Thirteen samples were chosen randomly to be sequenced. Primers for amplification
the region 16S-23S ITS region were chosen from literature. The primers sequences
are: MYITSF (5’-GATTGGGACGAAGTCGTAACAAG-3’) and MYITSR (5’AGCCTCCCACGTCCTTCATCGGCT-3’), manufactured by BioBasic. The reaction
mixture volume was 50 μl and prepared by mixing 25 μl master mix (cat. no.
RR310A, Takara Bio. Inc.), 1.875 μl of both the forward and reverse primer type from
stock solution 10 μM , 5 μl of DNA template and 12.5 μl of NFW. The amplification
conditions were slightly modified to initial denaturation at 95 °C for 5 min followed
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by 35 cycles of (95 °C for 1 min, 55 °C for 30 sec and 72 °C for 1 min) , and 72 °C
for 7 min (1 cycle) [30]. Thirteen samples (92, 272, 187, 392, 300, 445, 348, 100, 98,
265, 447, 394, and 114) were chosen randomly and amplified (table 10). All the
amplicons were examined on 2% agarose for gel electrophoresis and then were
sequenced by Macrogen (Seoul, South Korea). Then the forward and reverse
sequences were assembled by AlignX Vector NTI 11.5 software (Life technologies,
Carlsbad, California, USA) and finally analyzed by NCBI database.

2.3.3. Identification of drug resistance mutations of MDR-TB by Multiplex Allele
Specific (MAS) PCR
The reaction mixture was 25 μl prepared as follows: 12.5 μl master mix (cat. no.
RR310A, Takara), 1 pmol rpoB 516, 5 pmol rpoB526 , 32.5 pmol rpoB531 , 30
pmol RIRm , 1 pmol katG0F, 1 pmol katG5R , 2 μl of DNA template and the final
volume is completed by NFW (tables 11, 12). The PCR conditions consisted of an
initial denaturation at 96 °C for 3 min, 25 cycles of 95°C for 50 sec, 68°C for 40 sec,
and 72°C for 60 sec, and a final extension at 72°C for 7 min [81]. Amplicons were
visualized on 2% wt/vol agarose gel stained with ethidium bromide.

2.4. AuNPs-based sensors for MTB DNA detection
2.4.1. Cationic AuNPs-based sensor

2.4.1.1. Cationic AuNPs synthesis
Ten milliliter of 0.1% (w/v) chitosan (cat. no. 448869 Sigma Aldrich) in 1% acetic
acid was allowed to boil, then 0.5 ml of preheated 10mM gold (III) chloride trihydrate
(cat. no. 520918, Sigma Aldrich) added and mixed for 45 min. Characterization was
performed by Zeta sizer (Malvern Zeta sizer 3000HSA; Malvern Instruments Ltd.,
Malvern, UK) and Scanning electron microscope (SEM) (LEO SUPRA 55; Carl Zeiss
AG, Oberkochen, Germany).
2.4.1.2. Amplification of MTB DNA by IS6110 primers
PCR was performed with 5µl (50 ng) of template DNA in a reaction mixture (50 µl)
containing 12.5 μl master mix (cat. no. RR310A, Takara), 1 µM primer from each
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forward

5’-CCTGCGAGCGTAGGCGTCGG-3’

and

reverse

5’-

CTCGTCCAGCGCCGCTTCGG-3’. The PCR started with a denaturation step (94°C
for 3 min), followed by 35 cycles of denaturation (94°C for 1 min), annealing (68°C
for 1 min), and extension (72°C for 1 min), and a final extension step at 72°C for 5
min as described by Kocagoz et al. [21]. Amplicons were visualized on 1.5% wt/vol
agarose gel stained with ethidium bromide.

2.4.1.3. Amplification of MTB DNA by rpoB primers
PCR was performed with 5µl (50 ng) of template DNA in a reaction mixture (50 µl)
12.5 μl master mix (cat. no. RR310A, Takara), 1 µM primer (each) (forward 5’CGTACGGTCGGCGAGCTGATCCAA

-3’

and

reverse

5’-

CCACCAGTCGGCGCTTGTGGGTCAA -3’). The PCR conditions are 95 °C for 5
min, 30 cycles at 95°C for 30 sec, then at 72°C for 60 sec, and 72°C for 5 min as
described before [26]. Amplicons were visualized on 1.5% wt/vol agarose gel stained
with ethidium bromide.

2.4.1.4. Cationic AuNPs assay
The assay was performed by mixing 5µl of the cationic AuNPs and 20ul of amplified
product. The mixture left for 10 minutes before detection the color change.

2.4.1.5. Detection limit for cationic AuNPs assay
Serial dilutions were prepared after amplifying MTB H37Ra sample. The initial DNA
concentration was calculated by measuring the absorption at 260 and 280 nm using
UV-Vis spectrophotometer (model 7315, Jenway, UK). DNA concentration was
calculated using the following equation:
DNA Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50
µg/ml
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2.4.2. AuNPs-based FRET sensor for detection of MTB
2.4.2.1. Anionic AuNPs synthesis
Citrate reduction method of AuNPs was followed as previously described [68].
Briefly, 35 ml of 0.25 mM gold (III) chloride trihydrate (cat. no. 520918, Sigma
Aldrich) and equal volume of 2.5 mM of sodium citrate dibasic trihydrate ( cat. no.
C7254, Sigma Aldrich) were placed separately in two glass beakers, covered with
aluminum foil and heated. When the gold (III) chloride trihydrate started to boil,
sodium citrate was added and left to stir for 40 minutes till the solution color turned
bright red. For concentration, 1.5 ml of the colloid solution was centrifuged at 14,000
rpm for 20 minutes, and then the supernatant was dissolved in 200 µl nuclease free
water. Characterization was performed by zeta sizer and SEM.

2.4.2.2. Probe sequence
CY-3 labeled 16s rDNA specific probe was used. The sequence of the probe was CY3- 5ʹ CACCACAAGACATGCATCCCG-3ʹ (BioBasic) [55].

2.4.2.3. Optimization of the FRET assay
Hybridization buffer was prepared as follows; 2.5 µl of 500 mM NaCl, 1 µl of 1µM
CY-3 labeled probe and the final volume is completed to 10 µl by NFW. Serial
dilutions of the AuNPs were added to the hybridization buffer. Fluorescence was
measured to detect the optimum concentration of AuNPs for the assay; excitation and
emission were measured at 544 and 584 nm [82], respectively (BMG Labtech 4133179, Ortenberg, Germany).

2.4.2.4. Detection of MTB DNA using FRET assay
Extracted DNA was added to 8ul hybridization buffer then fragmented by 5%
sonication at 50 °C for 10 min dark (Sonorex digital 10p, Bandelin, Dusseldorf,
Germany). Then the samples were subjected to denaturation for 3 min at 95 ºC
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followed by annealing at 52 ºC for 45 sec by the thermal cycler. After incubation at
room temperature for 15 min, 40 µL of AuNPs were added to each sample. Excitation
and emission were measured at 544 and 584 nm, respectively.
2.4.2.5. Detection limit of FRET assay
Serial dilutions of H37Ra reference strain sample were prepared and the test was run
as previously described. The initial DNA concentration was calculated by measuring
the absorption at 260 and 280 nm using UV-Vis spectrophotometer. DNA
concentration was calculated using the following equation:
DNA Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50
µg/ml

2.5. Data interpretation and statistical analysis:
The sensitivity and specificity were calculated by the following equations:
Sensitivity = no. of true positive / (no. of true positive + no. of false negative) ×100
Specificity = no. of true negative / (no. of true negative + no. of false positive) × 100
Relative fluorescence was calculated for each test by normalizing fluorescence values
against residual fluorescence values. Unpaired Mann-Whitney U test was used for
comparison between the two sample sets (GraphPad Prism version 4.0 for Windows,
San Diego California, USA).
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Chapter 3: Results
3.1. Clinical bacterial strains
Mycobacterial DNA was extracted from 72 clinical isolates of infected patients.
Patients' gender distribution was 57 males and 15 females. All 72 Mycobacterial
samples were characterized by multiplex PCR and FRET. Two reference strains of M.
smegmatis and H37Ra were cultivated and used as negative and positive controls,
respectively. Isolates of different non-mycobacterial pathogens were also recruited
and investigated by both multiplex PCR and FRET. They involved four E.coli strains,
Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia and
Enterobacter aerogenes.

3.2. Characterization of the bacterial strains by PCR

3.2.1. Species differentiation by Multiplex PCR
DNA extracted from all (n=72) isolates (mycobacterial and non-mycobacterial) was
amplified via multiplex PCR, and then analyzed by gel electrophoresis. Based on
amplicon size reported by primer-BLAST of utilized primers, a clear 235 bp band was
observed for H37Ra sample (positive control), while M. smegmatis (negative control)
yielded band at 136 bp. Accordingly, 70/72 of tested samples yielded bands at 235 bp
and were classified as MTB, while 2/72 yielded bands at 136 bp and were classified
as NTM (figure 13). All amplicons of non-mycobacterial pathogens yielded no bands
on gel electrophoresis.

3.2.2. Amplification of 16S-23S ITS and Sequencing
Randomly selected 13 samples out of total 72 samples (13/72) had amplicon size of
350 bp on gel electrophoresis (figure 14). Such samples were subjected to forward
and reverse sequencing. Clear sharp peaks with limited background noise appeared in
the sequencing results (figures 15, 16). The forward and reverse sequences were
assembled and analyzed by NCBI database. Twelve samples (12/13) were reported as
MTB while only one sample (1/13) was reported as NTM (M. kansasii). The
concordance of the sequencing with the FRET assay was 100%.
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3.2.3. Identification of drug resistance mutation of MDR-TB by MAS- PCR
According to the results of DST conducted on cultures, 8 samples were found to be
rifampicin resistant, 12 samples were isoniazid resistant and 5 samples were MDRTB. The remaining samples were susceptible to rifampicin and isoniazid. Two NTM
samples were reported among the isoniazid resistant samples. The samples were
investigated by MAS PCR in which one of the primers is attached at a certain site and
the other primers are supposed to attach in the mutation site in case of wild type only
(figure 17). Concerning rifampicin resistance, 4 from 8 resistance mutations were
identified: two samples had mutation in the position rpoB 516; other two had
mutation at rpoB 531. For isoniazid resistance, only 3 samples from 12 were found to
have the mutation in KatG 315. None of drug susceptible samples had any mutations
when investigated by PCR (figure 18).
3.3. AuNPs based sensors for MTB DNA detection

3.3.1. AuNPs Characterization
Characterization of anionic and cationic AuNPs was performed by SEM and Zeta
sizer. SEM images showed spherical particles of uniform size and shape (figures 19,
21). The average diameters of anionic and cationic AuNPs were 40 nm and 20 nm,
respectively. Zeta sizer report revealed similar sizes' distribution and zeta potential of
-19 mV for the anionic AuNPs (figures 20, 22).

3.3.2. Cationic AuNPs-based sensor

3.3.2.1. IS6110 amplification of MTB DNA
All the 72 samples were amplified by the IS6110-specific primers according to
previously discussed conditions. Amplicons were tested on the gel electrophoresis.
All MTB samples have band at 123 bp (figure 23). None of the negative strains had
bands on gel.
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3.3.2.2. rpoB amplification of MTB DNA
All the 72 samples were amplified by the rpoB-specific primers according to
previously discussed conditions. Amplicons were tested on the gel electrophoresis.
All MTB samples had band at 235 bp (figure 24). None of the negative strains had
bands on gel electrophoresis.

3.3.2.3. Cationic AuNPs assay and Detection Limit
The presence of amplified DNA products provided a color shift of the cationic AuNPs
from red to blue (figure 25). Amplified MTB clinical samples showed violet-to-blue
color with AuNPs. The red color of AuNPs persisted after adding PCR products of
negative controls (figures 26, 27). Serial dilutions of the MTB H37Ra were prepared
and investigated by the cationic AuNPs assay. By calculating the initial DNA
concentration, the detection limit was found to be 5.4 ng/μl (figure 28).

3.3.3. AuNPs-based FRET assay for MTB DNA detection

3.3.3.1. Optimization of FRET assay and investigation of the clinical bacterial
strains by FRET
The least volume of the AuNPs to induce complete quenching of the fluorescence was
determined by mixing gradual volumes of the AuNPs and the hybridization buffer
containing CY-3 probe. The least volume that induced complete quenching was 40 μl
(table 13).
For proof-of-concept (figure 29), we first tested samples of both positive (MTB
H37Ra) and negative (M. smegmatis) controls by multiplex PCR and FRET assay.
Both assays succeeded to discriminate between samples. By FRET assay, the
fluorescence yield of positive control exceeded 3-fold higher than that of negative
control.
FRET assay was performed on all 72 samples of mycobacterial species. Seventy
samples (70/72) were identified to be MTB by multiplex PCR, of which, sixty nine
samples displayed fluorescence 3-fold higher than the negative control, so exceeding
the proposed cut off value. Only 1 sample had lower fluorescence than the cut off
value, which means a false negative result. Two samples (2/72) were identified to be
30

NTM by multiplex PCR and FRET, both displayed fluorescence 3-fold lower than
that of the negative control, indicating that they were NTM.
Also, 8 negative samples which are the non-mycobacterial pathogens (four E. coli
samples, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia,
and Enterobacter aerogenes) were investigated by both multiplex PCR and FRET.
Only the Enterobacter aerogenes sample had a high fluorescence exceeding the cut
off value which means it is a false positive result. The remaining seven samples had
lower fluorescence than the cut off value.
To summarize, of total 72 Mycobacterium samples tested, one false negative was
recorded; of 8 non-mycobacterial samples, one false positive was detected, translating
to sensitivity and specificity of 98.6% and 90%, respectively. The concordance
between the Multiplex PCR and FRET methods was 98% (figure 30).
3.3.3.2. Detection limit by FRET
Serial dilutions of the sample H37Ra were prepared to detect the detection limit of the
FRET assay. The initial DNA concentration was found to be 40 ng/µl, and the
detection limit is 10 ng/ µl. So the detection limit for the assay without prior DNA
amplification was determined to be 10 ng/ µl (table 14).
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Chapter 4. Discussion
TB diagnosis has always been challenging, since accuracy, affordability and short
time-to-result are critical properties of a novel assay for point-of-care. Two AuNPsbased MTB assays developed in this study offer rapid and accurate method for MTB
detection utilizing the minimum laboratory infrastructure. The main purpose of the
two assays is differentiation of MTB from NTM as initial culture does not allow
species differentiation because the colonies morphology of most mycobacteria species
is nearly the same. So differential culture, biochemical assays or molecular assays are
required for species differentiation [10].
Seventy two anonymous sputum samples were collected from patients from different
regions in Egypt. The sputum was decontaminated and cultured on LJ media in the
Central laboratories. MTB H37Ra and M. smegmatis were the positive and negative
control and were also cultured on LJ media in addition to 8 negative strains. The DNA
was extracted according to the manufacturer’s protocol. DNA extraction of the
mycobacterial species and other gram positive species was started by lysis of the rigid
cell wall by lysozyme enzyme.
Characterization of the clinical samples was verified by multiplex PCR to allow the
differentiation of MTB form NTM. Two sets of primers were used and each of them
amplifies its target and yields amplicons of different sizes. The primers are specific
for the region rpoB region which allowed species differentiation due to its variability
to differentiate between mycobacterial species. The MTB samples yielded amplicons
of size 235 bp while NTM samples yielded amplicons at 136 bp when they were
analyzed by gel electrophoresis. Seventy samples were characterized as MTB and
only two samples were found to be NTM.
Further verification of the samples was done by sequencing. Random samples were
chosen and amplified by 16S-23S ITS specific primers. All the amplicons were 350
bp in size. This hindered differentiation of MTB from NTM sample because the
amplicons size is nearly the same but the sequence is different. The amplicons were
then subjected to forward and reverse primer walking sequencing followed by
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assembling by AlignX Vector NTI 11.5 software. Then finally the resulting sequences
from the assembly were analyzed by NCBI database. The sequencing result was 12
MTB samples and 1 sample was NTM (M. kansasii). The concordance between the
sequencing and the multiplex PCR was 100%.
MAS-PCR was used to report the most common point mutations associated with
MDR-TB, since rifampicin and isoniazid are the most powerful antibiotics against
MTB bacilli. DST was first performed by culture in the Central laboratories. MASPCR was done using 4 sets of primers to identify the point mutations. In case of wild
type, the selected primers properly hybridized to the DNA template and amplify it. In
case of mutation in the hybridization site, primers could not hybridize to the target
and no amplicons were obtained. This reaction was highly specific and sensitive to
detect single point mutation. The reported DST profiles were compared with PCR
results. Only the main mutations were detected within the rpoB for rifampicin
resistance and KatG for isoniazid resistance. Concerning rifampicin resistance, 4 from
8 resistance mutations were identified: two samples had mutation in the position rpoB
516; other two had mutation in the rpoB 531. For isoniazid resistance, only 3 samples
from 12 were found to have the mutation in KatG 315. The resistant samples of
undetected mutation have other mutations which are less common and were not
investigated by their corresponding primers here.
Two AuNPs-based sensors were developed to allow colorimetric and fluorormetric
detection of MTB. The first sensor is the AuNPs-based sensor for colorimetric
detection of MTB DNA. The targets were IS6110 and rpoB genes. IS6110 is a nonencoding insertion transposal sequence and repeated up to 25 times along the MTB
genome. It has been a common target when developing assay targeting MTB [22, 56].
The rpoB gene is encoding for the β-subunit of RNA-polymerase of MTB and has
been targeted by distinctive primers for either MTB detection or identification of
rifampicin resistance associated mutations [16, 18]. The cationic AuNPs were
synthesized using chitosan, acetic acid and gold (III) chloride trihydrate. The AuNPs
were spherical in shape with average diameter 20 nm. The principle of the cationic
AuNPs assay is based on the unique physicochemical properties known as SPR,
which is responsible for characteristic color of the AuNPs. Freely dispersed AuNPs
show a red color. When the inter-particle distance decreases, the color changes from
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red to blue due to the red shift in the absorption spectrum to a higher wave length in
the UV-visible spectrum. The change in the absorption results from the plasmonplasmon coupling of the aggregated AuNPs [69]. In case of positive samples where
the target DNA sequence is present, the amplicons are yielded after hybridization of
the primers. Negative-charged DNA were attracted to positively- charged AuNPs,
leading to their aggregation, thus, color shifts from red to blue. However, in case of
negative samples, no amplicons were obtained and AuNPs remained dispersed, thanks
to the repulsion forces between the AuNPs which keep the intra-particle distances
constant. Subsequently, the color remains red and no color shift occurs. The detection
limit was determined by preparing serial dilutions of MTB H37Ra samples. Initial
DNA concentration was calculated after measuring the samples absorption at 260 and
280 nm and was found to be 40 ng/µl. The last tube that displayed color change
contained 5.4 ng/μl DNA (detection limit).
The second sensor was AuNPs-based FRET for fluorometric detection of unamplified
MTB DNA. Citrate reduction method was attempted for the synthesis of anionic
AuNPs. Sodium citrate dibasic trihydrate was used to reduce the gold (III) chloride
trihydrate. The result was citrate coated AuNPs of negative charge. The AuNPs size
was 40 nm because this size displays the maximum absorption capacity so offers
sufficient quenching of the fluorescence. The CY-3 dye was chosen because it has
been used extensively to evaluate FRET phenomenon. The excitation and emission
(544 and 584 nm) were measured according to the previous experiments [59, 61, 63].
The probe sequence was chosen to target 16s rDNA region because it has hyper
variable regions that differentiate the different species of the mycobacterium genus
and has been investigated before to allow accurate detection of MTB by AuNPs [9,
55]. The assay was first optimized by setting the minimum AuNPs volume sufficient
to induce the maximum fluorescence quenching. This was accessed by gradually
increasing volumes of AuNPs added to the hybridization buffer using blank sample
(water) instead of DNA. The adequate volume was found to be 40 µl of 40 nm AuNPs
while larger volumes did not decrease the fluorescence significantly. The anonymous
samples (n=72) in addition to the positive and negative controls were investigated by
FRET sensor. When the target MTB DNA was present, the probe hybridized with the
CY-3-16s rDNA specific probe and the more stable dsDNA structure was formed.
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This exposes the negatively charged phosphate backbone to the outer media where the
negatively charged AuNPs are present; resulting in repulsion and adsorption of the
AuNPs to the DNA is prevented. Consequently, the AuNPs is spaced from CY-3 and
fluorescence is emitted. In case of absence of the target DNA as in the M. smegmatis
and the negative controls, the AuNPs become in close proximity to the CY-3 probe
and quench the fluorescence for the following reasons. First, there is binding affinity
of CY-3 fluorophore towards AuNPs (the energy of the hybridization is 80-100
kcal/mol and the adsorption energy of the fluorophore on the AuNPs surface is 8-16
kcal/mol ) [59]. Second, the inter-particle repulsion between the AuNPs enhances the
adsorption of the AuNPs on the CY-3 labeled probe. Third, the non-radiative energy
transfer between the AuNPs and the CY-3 (fluorophore) enhances the quenching of
the fluorescence [83]. By FRET, 69 from 72 samples were found to be MTB which
means they had relative fluorescence exceeding the estimated cut-off value that was
three folds the negative control. Of total 72 Mycobacterium samples tested, one false
negative was recorded; of 8 non-mycobacterial samples, one false positive was
detected, translating to sensitivity and specificity of 98.6% and 90%, respectively.
The concordance between the multiplex PCR and FRET methods was 98%. The
concordance of the FRET assay, multiplex PCR, and sequencing was 100%.
The detection limit was determined by the DNA of the reference strain MTB H37Ra.
Serial dilutions were prepared of the sample then the hybridization buffer was
prepared. The least concentration that displayed fluorescence higher than the relative
cut-off value was the detection limit. The initial sample concentration was calculated
after measuring the absorption at 260 and 280 nm and was found to be 40 ng/μl. The
last positive fluorescence was obtained after the dilution of the sample to the quarter
so the detection limit of the assay 10 ng/μl.
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Chapter 5: Conclusion and Future Perspectives
Fast and accurate diagnosis leads to better clinical and socioeconomic outcomes. Also
reduces the chances for the spread of the disease will be precluded and the
development of drug resistance will be averted. So the drug regimens will be shorter
and more effective.
The developed assays detected MTB DNA with high accuracy and sensitivity. The
cationic AuNPs based assay detected the amplicons of the MTB DNA by just one step
which is the addition of the AuNPs. The color change is observed visually without the
need for any instruments. This assay can circumvent the gel electrophoresis that needs
several preparation steps and the use of the toxic chemical ethidium bromide. The
second assay is the AuNPs-based FRET assay. The DNA was not exposed to previous
enzymatic digestion and amplification. The preparation of the sample needs simple
steps after the DNA extraction. The assay is performed by just the use of the CY-3
probe and the cost of the amplification is saved. The results are obtained shortly after
the DNA is extracted by observing the fluorescence. The cut-off value was the 3 times
of the base fluorescence and the positive samples are obviously discriminated from
the negative samples. Due to the low cost and accuracy of the FRET assay, it can be
extended for the diagnosis of TB in limited resources countries.
Several developments can be introduced to improve the detection of TB. Non-sputum
samples as the saliva, urine and the exhaled air should be validated for culturing and
further investigation. DNA extraction may be improved by the use of beads to replace
the sophisticated and expensive extraction kits. The colorimetric assay performance
can be improved by the development of specific reader to avoid personal difference
when judging color change and the results are analyzed spectrophotometrically. Also
drug resistance can be investigated by the use of specific probes for the mutation sites.
The FRET assay can be easily manipulated to detect the resistance associated
mutations. Probes specific for the mutation points can be synthesized tagged to
specific fluorophore. Different fluorophores with distinctive excitation and emission
can be used to allow the diagnosis and DST in the same time.
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6- Tables
Table 1. First line antibiotics, mode of action and main adverse effects [2, 6, 16,
84, 85]
Drug name

Characteristics

Mode of action

Main adverse effects

Rifampicin

Semisynthetic

Inhibits the transcription

- Allergic reaction

derivative of

of the β-subunit of the

- Gastrointestinal

rifamycin

RNA polymerase

Isoniazid

discomfort

Prodrug which is Alters the synthesis of the

- Neuropathy

activated in the

- Allergic reaction in the

mycolic acids

-

human cell by

skin

bacterial catalase
peroxidase
Ethambutol

Activated in

Inhibits the attachment of

vivo

the mycolic acids to the

- Reversible optic neuritis

cell wall
Streptomycin

Aminoglycoside

Inhibits bacterial proteins

- Renal toxicity

antibiotic

synthesis by binding to the - Ototoxicity
30S ribosomes subunit
which is involved in
translation of mRNA

Pyraziamide

Prodrug used to

Increases the pH of the

treat tuberculosis cytoplasm so alters the

- Gastrointestinal
discomfort

activated by the

normal membrane

- Allergic reaction

enzyme

pressure

- Liver toxicity

pyrazinamidase
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Table 2. Genes of the common mutation(s) in the resistant MTB strains [2, 6, 16, 17, 84-87]
Drug

Rifampicin

Genes of common

Normal gene role

Frequency relative

Effect of the

mutation(s) in resistant

to the resistant

associated

strains

strains

mutation

β-subunit of RNA polymerase

RpoB

90-95%

526( H to P, D, Y)

High resistance

81-bp region which is called

531 (S to L)

High resistance

Rifampicin

511( L to P)

Low resistance

516 (D to V , Y)

High resistance

519 (N to Y)

Low resistance

Resistance-

Determining Region (RRDR)

Isoniazid

Mutation site

InhA

Production of enoyl-acyl carrier

30%

522 (S to L)

Low resistance

inhA promoter

protein reductase

30%

15

Moderate resistance

KatG

Production

50-90%

315 (S to L)

Moderate resistance

60%

120

of

catalase

and

peroxidase
Pyrizamide

PncA

Production of the activating
enzyme: pyrazinamidase

Ethambutol

Streptomycin

embB

RpsL

Arabinosyl transferase

The ribosomal protein S12
production

different

point

High resistance

mutations
20-70%

52-59%

306

Moderate resistance

330

High resistance

630

High resistance

330

High resistance

630

High resistance
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Table 3. Comparison between the most applicable diagnostic approaches of TB.
Diagnostic

Target

Advantage

Disadvantage

References

MTB bacilli

- Fast, cheap, simple

-Low sensitivity up to 50%

[29, 30]

approach
Smear
microscopy

-Misdiagnose HIV coinfected patients due to their
low bacterial load

Tuberculin

TB proteins

skin test

-Fast, cheap, simple

-Does not discriminate

-Can detect latent

between infection and

infection

vaccination so yields false

[12, 29, 30]

positive results
-Additional assays should
be done to confirm infection
Culture

MTB bacilli

-Accurate and

-Need long time to obtain

sensitive

the results

-Allows drug

- Costly infrastructure

susceptibility testing

- The personnel need prior

[29]

training for safety
- Does not allow species
differentiation
Serological

Anti-tuberculous

-Does not need

- Sensitivity is low in HIV

assays

antibodies

complicated

patients

[29, 32]

infrastructure
-Discriminate
infection from
vaccination
NAATs

DNA

- Fast and accurate

-Costly infrastructure and

[10, 29, 38,

- Allows species

consumables

51]

differentiation

-Trained personnel are

- Allows DST

required

- Low contamination
risk
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Table 4. Commercially available NAATs for MTB detection
Reaction

Assay’s name Target

Specimen

type

and fabricator

type

Real time

Cobas

PCR

Amplicor,

16s rDNA

Clinical

Sensitivity

Ref.

93%

[10, 29, 38, 88-

specimens

93]

Roche
Nested real

GeneXpert

time PCR

MTB/Rif ,

rpoB gene

Clinical

90%

[29, 94-96]

93%

[10, 29, 52, 97,

specimens

Cepheid
Isothermal

Amplified

transcription

Mycobacterium

mediated

tuberculosis

rRNA

Clinical
specimens

98]

amplification direct,
Genprobe
Strand

Becton

IS6110 and

Clinical

93%

[10, 29, 38, 90,

displacement

Dickson, BD

16srDNA

specimens

99, 100]

[29, 93, 101]

amplification probe tech

Loop

LAMP , Eiken,

16s rRNA,

Sputum

mediate

Japan

gyrB

samples

Polymerase

Inno-LiPA

16s-23s rRNA

Sputum and

chain

Rif.TB line

culture

reaction

probe assay ,

samples

amplification
100%

[29, 38, 90]

90%

[29, 38, 90]

Innogentics,
Belgium
Polymerase

Genotype

23s rRNA,

Sputum and

chain

Mycobacterium Mutations in

culture

reaction

and Genotype

rpoB, KatG

samples

MTBDR plus

and inhA genes

assay, Hain
lifescience,
Germany
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Table 5. Pipeline for the development phases of TB diagnostic technologies.
Retrieved from [24].
A. High complexity assays.

Early development

Late or completed
development

On pathway to
WHO evaluation
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B. Moderate complexity assays.
Early development

Late or completed
development

On pathway to
WHO evaluation

Molecular Detection/DST
Xtend XDR (Cepheid)

Genedrive MTB/RIF (Epistem)

Alere Q (Alere)

Truelab/Truenat MTB (Molbio)

Enigrna
ML
Diagnostics)

(Enigrna

TB LAMP (Eiken)

Xpert Ultra (Cepheid)

Q-POC (QuantuMDx)
EOSCAPE (Wave80)
TBDx system (KGI)
X1 (Xagenic)
MTB Detection (Tangen
Biosciences)

Cellular Response- Detection/Latent and Latent to active progression
T-Track TB (Lophius)
TAM-TB (LMU/Alere)

QuantiFERONTB
PLUS
(Qiagen)

EAST-6/CFP-10 skin test
(SSI)

Diaskin
(Generium)
Breath biomarker-Detection

BreathLink (Menssana)
Prototype breathanalyzer
(Next Dimensions Tech)
TB Breathalyser (Rapid
Biosensor Systems)
Aeonose
(The
Company)

eNose

42

C. Low complexity assays.

Early development

Late or completed
development

On pathway to
WHO evaluation

Antigen, Antibody and Biomarker detection- Detection

LAM in sputum (Standard
Diagnostics)

Alere Determine TB-LAM in
urine (Alere)

IRISA-TB (Antrum Biotec)
Enzymatic-Detection/DST
β-lactamase
reporter (Global
BioDiagnostics)
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Table 6. WHO recommendation: Role of NAATs in TB diagnosis. Retrieved
from [24].

a: assays can be used in NTM
b: DST can be used also for TB diagnosis
Dx: Diagnosis
DST: Drug Susceptibility Testing
WGS: Whole Genome Sequencing
Ref.: Reference laboratory, Int.: Intermediate Laboratory, Per.: Peripheral Laboratory
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Table 7. Comparison between the main diagnostic assays for detection of MTB by AuNPs.

AuNPs type

Size

of Sample

PCR cycles

spherical

Turnaround

Target

time

AuNPs
un modified

14 nm

AuNPs

Sensitivity

Detection

and

limit

Ref.

specificity
extracted 16s rDNA : 1 hour
30 cycle,
from
culture,
Semi-nested
digested
by
PCR:
25
BamH1 enzyme
cycles
DNA

16s rDNA

100%

and 1 ng/µl for [55]

100%

PCR product/
40

ng

for

genomic
DNA

13 nm

Blood samples

35 cycles

1 hour

IS6110

2.6 nM

[28]

45

Thiolated

13 nm

Cultures

35 cycles

49 sputum, 6

30 cycles

25-40 min gyrB locus

[73]

AuNPs
RNA polymerase 100%

0.75 µg/µl

[72]

18.75 ng/µl

[74]

0.5 pmol

[71]

β_subunit

bronchial
washes,

7

pleural effusion,
6 urine and 5
blood samples.
15-20 nm

Stool samples

16S-23S ITS DNA

87.5%
and 100%

13.7 nm

DNA

extracted 40 cycles and 1 day

from
prepared

cultures 14 cycles
from

sputum samples

IS6110, Rv 3618 96.6%
DNA

and
98.9% for
MTBC
and
94.7%
and
99.6% for
MTB
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Table 8. Assays developed for fluorometric detection of MTB
Assay type

Fluorophore

Target

Sensitivity

Ref.

and
specificity
Upconversion

Lanthanide

nanoparticles

nanoparticles and

detection of MTBC

SYTOX orange dye

Sandwich-form

Cadmium telluride

AuNPs based FRET

quantum dots

IS6110

100% and

[76]

100%

ESAT-6

94.2% and

[77]

86.6%

for detection of the
MTBC
Drug resistance

LCRed640 and

Point

76% and

detection by Real-

fluorescein

mutations in

100%

time PCR

[78]

the genes
inhA, KatG
and ahpC

Drug resistance

Texas red, fluorescein,

detection by

tetrachlorofluorescein,

molecular beacons

tetramethylrhodamine,

rpoB gene

97% and

[79]

100%

rhodamine
Detection of MTB

Fluorescent silica

bacilli

nanoparticles and

MTB bacilli

[62]

SYBR-green
Detection of MTB

Monoclonal antibodies

bacilli

with fluorescent silica

MTB bacilli

97.1% and

[80]

91.35%

nanoparticles
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Table 9. The primers and amplicons sizes used to differentiate between MTB and
NTM
Forward primer

Reverse primer

Amplico

Identificatio

n size in n

Ref
.

bp
5’-

5’-

TACGGTCGGCGAGCT

ACAGTCGGCGCTTG

GATCCAAA-3’

TGGGTCAAC-3’

5’-

5’-

235

MTB

[30]

136

NTB

[30]

GGAGCGGATGACCAC CAGCGGGTTGTTCT
CCAGGACGTC-3’

GGTCCATGAAC-3’

MTB: Mycobacterium tuberculosis
NTM: Non-tuberculous Mycobacterium
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Table 10. Samples chosen randomly and their sequencing results
Sequenced Samples

Sequencing result

Reference

95

NTM

Alexandria governorate

272

MTB

Abasia chest hospital, Cairo
governorate

187

MTB

Dakahlia governorate

392

MTB

Giza chest hospital, Giza
governorate

300

MTB

Dakahlia governorate

445

MTB

Abasia chest hospital, Cairo
governorate

348

MTB

Alexandria governorate

100

MTB

Alexandria governorate

98

MTB

Alexandria governorate

265

MTB

Abasia chest hospital, Cairo
governorate

447

MTB

Abasia chest hospital, Cairo
governorate

394

MTB

Giza chest hospital,

Cairo

governorate
114

MTB

Alexandria governorate
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Table 11. The primers used for identification of drug resistance associated mutations [80]
Target site of Primer

Forward primer

Primer

Reverse primer

Amplicon size

5’-ATACGACCTCGATGCCGCT-3’

KatG0F

5’-

293

mutation
KatG at 315

KatG5R

GCAGATGGGGCTGATCTACG3’
rpoB at 516

rpoB516

5’-CAGCTGAGCCAATTCATGGAC-

RIFm

5’-TTGACCCGCGCGTACAC-3’

218

3’
rpoB at 526

rpoB526

5’-CTGTCGGGGTTGACCCA-3’

RIFm

5’-TTGACCCGCGCGTACAC-3’

185

rpoB at 531

rpoB531

5’-CACAAGCGCCGACTGTC-3’

RIFm

5’-TTGACCCGCGCGTACAC-3’

170
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Table 12. Amplicons size by MAS PCR. The presence of specific band size
indicates wild type while the absence of specific band size indicated mutation and
drug resistance.
Mutation site

Amplicon size in bp

KatG 315

293

rpoB 516

218

rpoB 526

185

rpoB 531

170
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Table 13. Optimization of AuNPs concentration for optimum quenching of
fluorescence. The red arrow is pointed at the optimum AuNPs volume used in the
FRET assay to quench the fluorescence.

40 nm AuNPs dilutions

Fluorescence

Hybridization buffer (10 µl) + 40 µl NFW

59185

Hybridization buffer + 30 µl NFW +10 µl 21908
AuNPs
Hybridization buffer + 20 µl NFW +20 µl 12782
AuNPs
Hybridization buffer + 10 µl NFW +30 µl 1235
AuNPs
Hybridization buffer + 40 µl AuNPs

968

Hybridization buffer + 50 µl AuNPs

955
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Table 14. Detection limit of FRET assay investigated by H37Ra sample.
Serial dilution of the DNA were prepared and fragmented in the hybridization buffer
then investigated by the FRET assay. The red arrow is pointed at the least DNA
concentration detected by FRET.

Positive control

Relative fluorescence

H37Ra

33.5

H37Ra (1/4)

14.4

H37Ra (1/16)

1.228

H37Ra (1/64)

0.876

H37Ra (1/128)

1.053
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7- Figures

Figure 1. Top causes of deaths worldwide. Deaths numbers are for 2012 (on the
top) and for 2014 (on the bottom). The gray part is the deaths due to HIV. The TB rate
was 1.5 million people while the HIV rate was 1.2 million. Retrieved from [3].

54

Figure 2. The incidence of TB worldwide in 2014. The number of TB patients and their geographic
distribution are shown in different colors according to the density. Retrieved from:
http://www.cdc.gov/travel-static/yellowbook/2014/map_3-13.png
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Figure 3. Tuberculosis Egypt profile. The figure is showing the incidence,
prevalence and mortality rate of TB, MDR-TB and HIV patients with TB. Figure
retrieved from [4].
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Figure 4. The cell wall of MTB. The mycolic acids appears attached to the
peptidoglycan in the cell wall of MTB bacilli. Retrieved from
http://www.nature.com/nrmicro/journal/v6/n4/images/nrmicro1861-f1.jpg

57

Figure 5. The pathophysiology of MTB inside the host. After inhalation of MTB
bacilli and in case of healthy person, some bacilli may sneak to the lower respiratory
tract. The macrophages hurry to the site of infection and destroy the bacilli. In case of
the failure of the macrophages to terminate the bacteria, the macrophages engulf the
bacilli forming Ghon complex. If the host’s immunity becomes weaker, this
granuloma may soften and the bacteria spread to the lung and other organs as the
lymph

nodes

resulting

in

active

infection.

Retrieved

from:

http://www.nature.com/nrmicro/journal/v12/n4/images/nrmicro3230-f1.jpg
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Figure 6. The MTB bacilli after ZN staining under the microscope. The bacilli
appear as red rods under a blue background. Retrieved from
http://commons.wikimedia.org/wiki/File:Mycobacterium_tuberculosis_ZiehlNeelsen_stain_02.jpg
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Figure 7. Digital chest X-ray. The left image is for digital chest X-ray. The right
image is for CAD4TB analysis (specific software analyzes the images to detect any
lung abnormalities) of the image. Both images show lung abnormalities. Retrieved
from [24].
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Figure 8. Tuberculin assay. The irritation is due to reaction with the injected
antigen. After 48 hours, the injection site is tested. If the diameter of the injection site
exceeded 10 mm in high risk people as infants, nurses, prisoners or HIV co-infected
patients, this indicates TB active infection. If the diameter was 15 mm or more and
there are no risk factors, this indicates active TB infection. Retrieved from:
http://www.healthcentral.com/common/images/9/9231_18546_5.jpg
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Figure 9. The Surface Plasmon resonance of AuNPs. When light with an electromagnetic
field of a wavelength larger than AuNPs diameter hits the AuNPs, the nanoparticles
induce a collective dipolar oscillation for the free electrons in the conduction around the
metal nanoparticles surface. When these oscillations reach the maximum, this
phenomenon is known as Surface Plasmon Resonance
Retrieved
from:
http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.sv
c/ImageService/Articleimage/2015/RA/c5ra01819f/c5ra01819f-f1_hi-res.gif
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Figure 10. The FRET energy transfer. The donor is excited by a certain wave
length. When the donor loses this energy as non-radiative energy, it transfers to the
acceptor if it is present in the proper distance (not less than 7 nm) that allows energy
transfer. The non-radiative energy transfer is called resonance.
1- Excitation of the donor by a photon from the ground state (S °) to the lowest
excited state (S1).
2- Energy photon release of the donor and returning to the ground energy state
3- Energy transfer from the donor to the acceptor and excitation of the acceptor
4- Release of photon from the acceptor
5- Energy release of the acceptor to the ground energy state
Retrieved from:
http://chemwiki.ucdavis.edu/Theoretical_Chemistry/Fundamentals/Fluorescence_Res
onance_Energy_Transfer
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Figure 11. Geographic distribution of the samples collected in Egypt. The
anonymous samples were obtained from patients of different geographic locations.
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Figure 12. Drug sensitivity results as obtained by culture. The sensitivity of the
first line antibiotics was investigated by culture in the Central Laboratories

65

Figure 13. Gel electrophoresis of multiplex PCR of mycobacterial samples. The
amplicons were investigated on 1.5% agarose gel stained with ethidium bromide and
visualized by UV. Samples 446, 277, 272, 448, 121, 275, 450, 443 and 119 were
proven to be MTB because the bands appeared at 235 bp. R: MTB H37Ra is the
reference strain and had a band at 235 bp. S: M. Smegmatis which is NTM had a band
at 136 bp. E: is E.coli sample did not have any band and c: control is just a blank by
water instead of the sample.
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Figure 14. PCR amplification of randomly chosen samples by 16S-23S ITS primers. The
randomly chosen samples were amplified and the amplicons were analyzed by 1.5% agarose
gel stained with ethidium bromide. All the bands appeared at 350 which only verify the
amplification but do not allow differentiation of the different species. The amplicons were
then sequenced.
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Figure 15. Sequencing peaks of sample 300. After the samples were amplified by
16S-23S ITS primers, the amplicons were purified and subjected to forward and
reverse primer walking sequencing by Macrogen, South Korea.
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Figure 16. NCBI BLAST analysis of sample 300. After assembling of the forward and
reverse sequences, the NCBI analysis was done.
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218 bp

185 bp
170 bp

293 bp

Figure 17. Primers sites for amplification of MTB mutation sites. Only wild type
allows amplification and mutated types do not yield any amplicons. Figure retrieved
from [81].
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Figure 18. Gel electrophoresis of MAS PCR of Mycobacterial samples. Sample
186 was proven to be rifampicin resistant by culture, by PCR, the band at 170 bp was
absent which means that rifampicin resistance is due to mutation in rpoB gene at 531
bp. Sample 267 was Isoniazid resistant by culture. However, the resistance was
probably due to other mutation rather than KatG gene.
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Figure 19. Anionic AuNPs characterization by SEM. After preparation of the
AuNPs without concentration, 10 µl are allowed to dry on aluminum foil covering a
glass slide. After complete dryness of the AuNPs, investigation is performed by SEM.
The particles are spherical, of nearly uniform size and the average diameter is 40 nm.
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Figure 20. Anionic AuNPs characterization by zeta sizer. After preparing the
AuNPs without concentration, 100 µl of the AuNPs are added to 1900 µl NFW and
then fill the cuvette from this dilution. The peak is at 40 nm.
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Figure 21. SEM imaging of cationic AuNPs. After preparation of the AuNPs without
concentration, 10 µl are allowed to dry on aluminum foil covering a glass slide. After
complete dryness of the AuNPs, investigation is performed by SEM. The particles are of

uniform shape and diameter. The average diameter is 20 nm.
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Figure 22. Zeta sizer characterization of cationic AuNPs. After preparing AuNPs
without concentration, 100 µl of the AuNPs are added to 1900 µl NFW and then fill
the
cuvette
from
this
dilution.
The
peak
is
at
20
nm.
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Figure 23. Gel electrophoresis of IS6110 amplification of bacterial strains.
Samples 335, 331, 358, 100, 98, 94, 300, 15, 17 and 12 are Mycobacterium
tuberculosis samples and yielded bands at 123 bp , E. coli (E) sample and M.
smegmatis (S) sample did not had any bands because they lack the amplified
sequence.
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Figure 24. Gel electrophoresis of rpoB amplification of bacterial strains: samples
335, 331, 358, 100, 98, 94, 300, 15, 17, 12, 4, 5 and 12 are Mycobacterium
tuberculosis samples and yielded bands at 235 bp. M. smegmatis (S) did not yield any
band.
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Figure 25. Diagram for Cationic AuNPs assay. In the case of positive samples, the
presence of the target DNA sequence resulted in formation of amplified DNA
product. The negative DNA charge will attract the positively charged AuNPs leading
to their aggregation and thus the appearance of the blue color. However, in case of
negative samples, no PCR product formed and the AuNPs remain dispersed. The
repulsion forces between the AuNPs keep the intra-particles distances constant,
subsequently, the colloidal color remains red. Azzazy ©.
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Figure 26. Cationic AuNPs assay of rpoB amplicons of MTB DNA samples. 335,
358, 331, 100 and 98. S: M. smegmatis sample. The MTB samples were amplified by
the rpoB primers then cationic AuNPs were added to the amplicons. The attraction
between the negatively charged amplicons and the positively charged AuNPs induced
the color from red to violet due to the AuNPs aggregation. The M. smegmatis was not
amplified because it lacks the complementary sequences for the primers hybridization
so the AuNPs remained dispersed.
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Figure 27. Cationic AuNPs assay of IS6110 amplicons of MTB DNA samples: 2,
4, 5, 6, 10, 11, 12, NI (M. smegmatis sample, pointed by red arrow), 17, 13, 15, 16,
14, 20, N2 (E.coli sample, pointed by red arrow). The numbered samples are MTB
samples and thus the tubes turned blue. The MTB samples were amplified by the
IS6110 primers then cationic AuNPs were added to the amplicons. The attraction
between the negatively charged amplicons and the positively charged AuNPs induced
the color from red to violet due to the AuNPs aggregation. The M. smegmatis was not
amplified because it lacks the complementary sequences for the primers hybridization
so the AuNPs remained dispersed.
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Figure 28. Detection limit by Cationic AuNPs assay of IS6110 amplicons. Serial
dilutions were prepared and investigated. The initial DNA concentration was
calculated after measuring absorption at 260 and 280 nm. The detection limit was the
least amount of DNA induced color change and was found to be 5.4 ng/µl.
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Figure 29. Diagram for FRET assay. In presence of the target in case of MTB
DNA, the probe hybridizes with the CY3-16s rDNA specific probe; the more stable
dsDNA structure is formed. This exposes the negatively charged phosphate backbone
to the outer media where the negatively charged AuNPs are present; resulting in
repulsion and adsorption of the AuNPs to the DNA is prevented. Consequently, the
gold nanoparticle is spaced from CY-3 and fluorescence is emitted. In absence of the
target as in the M. smegmatis and the negative controls, the AuNPs become in close
proximity to the CY-3 probe. Azzazy ©.
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Cut-off value

Figure 30. FRET results by CY-3 16s rDNA specific probe. The MTB samples were
above the cut-off value which is 3 folds the negative control value. The M. smegmatis and the
negative samples were under the cut-off value.
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